X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Ibyra (olaparib) is a poly (ADP-ribose) polymerase (PARP) inhibitor, which is approved in India for the treatment of HRD-positive and BRACA-positive cancer patients.
Lead Product(s): Olaparib
Therapeutic Area: Oncology Product Name: Ibyra
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 13, 2024
Details:
Saroglitazar is a first in class drug which acts as a dual PPAR agonist at the subtypes α (alpha) and γ (gamma). It is being evaluated for the treatment of Primary Biliary Cholangitis.
Lead Product(s): Saroglitazar magnesium
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2024
Details:
Imdur-Generic (isosorbide mononitrate) is a soluble guanylate cyclase activator which is approved by USFDA for the treatment of chest pain (angina) in patients with a certain heart condition.
Lead Product(s): Isosorbide Mononitrate
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Imdur-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 16, 2024
Details:
Rexigo (relugolix) is a nonpeptide GnRH receptor antagonist that competitively binds to pituitary GnRH receptors. It is launched in India for testosterone suppression in patients with advanced prostate cancer.
Lead Product(s): Relugolix
Therapeutic Area: Oncology Product Name: Rexigo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2024
Details:
Prezista (darunavir) is a protease inhibitor antiviral medicine which is approved by USFDA for the treatment of Human Immunodeficiency Virus (HIV-1) Infection.
Lead Product(s): Darunavir
Therapeutic Area: Infections and Infectious Diseases Product Name: Prezista
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2023
Details:
Under the terms of the agreement, Zydus will assume full responsibility for the clinical development and commercialization for leuprolide injectable in the US market, and Daewoong will be responsible for the pre-clinical studies, production and supply of the product.
Lead Product(s): Leuprolide Acetate
Therapeutic Area: Oncology Product Name: Lupron Depot-Generic
Highest Development Status: ApprovedProduct Type: Peptide
Recipient: Daewoong Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 12, 2023
Details:
Under the terms of this agreement, Zydus has granted Sun Pharma semi-exclusive rights to comarket an innovative drug, Rytstat (desidustat), first-of-its-kind oral treatment for anemia associated with Chronic Kidney Disease, in India.
Lead Product(s): Desidustat
Therapeutic Area: Hematology Product Name: Rytstat
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sun Pharmaceutical Industries Limited
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 30, 2023
Details:
Zituvio (Sitagliptin) tablets A is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Lead Product(s): Sitagliptin Phosphate
Therapeutic Area: Endocrinology Product Name: Zituvio
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2023
Details:
A fixed dose combination of vilanterol (adrenergic receptor beta-2 agonist), glycopyrrolate & fluticasone furoate is approved for the treatment of chronic obstructive pulmonary disease.
Lead Product(s): Vilanterol Trifenatate,Glycopyrronium Bromide,Fluticasone Furoate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2023
Details:
Indocin (indomethacin) suppositories is a nonsteroidal anti-inflammatory drug that is indicated for the treatment of moderate to severe rheumatoid arthritis.
Lead Product(s): Indomethacin
Therapeutic Area: Immunology Product Name: Indocin-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
